N. Dedes

TL;DR: A consensus definition of late presentation of HIV infection is presented to present to identify the extent to which late presentation occurs remains inadequate across Europe.

TL;DR: This work proposes adding a ‘fourth 90’ to the testing and treatment target: ensure that 90 % of people with viral load suppression have good health-related quality of life, which would expand the continuum-of-services paradigm beyond the existing endpoint of viral suppression.

TL;DR: The European HIV Drug Resistance Panel was established to make recommendations to clinicians and virologists on this topic and to propose quality control measures as mentioned in this paper, and the panel recommended resistance testing for the following indications: i) drug-naive patients with acute or recent infection; ii) therapy failure, including suboptimal treatment response, when treatment change is considered; iii) pregnant HIV-1-infected women and paediatric patients with detectable viral load when treatment initiation or change is considering; and iv) genotype source patient when post-exposure prophylaxis is considered

TL;DR: The HIV drug resistance prevention and assessment strategy, developed by the World Health Organization in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings.

TL;DR: The objective of the 1st European AIDS Clinical Society meeting on Standard of Care in Europe was to raise awareness of the European scenario and come to an agreement on actions that could be taken in the future.